Investing.com - Anebulo Pharmaceuticals reported on Friday first quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Anebulo Pharmaceuticals announced earnings per share of $-0.1 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.075 on revenue of $0.00.
Anebulo Pharmaceuticals shares are down 20.63% from the beginning of the year and are trading at $3.700 , down-from-52-week-high.They are outperforming the Nasdaq which is down 22.93% from the start of the year.
Anebulo Pharmaceuticals shares lost 7.27% in intra-day trade the report.
Anebulo Pharmaceuticals follows other major Healthcare sector earnings this month
Anebulo Pharmaceuticals's report follows an earnings beat by Medtronic on August 23, who reported EPS of $1.13 on revenue of $7.37B, compared to forecasts EPS of $1.12 on revenue of $7.22B.
Agilent Technologies had beat expectations on August 16 with third quarter EPS of $1.34 on revenue of $1.72B, compared to forecast for EPS of $1.2 on revenue of $1.64B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar